Co-occurring WARS2 and CHRNA6 mutations in a child with a severe form of infantile parkinsonism.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
03 2020
Historique:
received: 27 09 2019
revised: 10 02 2020
accepted: 11 02 2020
pubmed: 3 3 2020
medline: 30 1 2021
entrez: 3 3 2020
Statut: ppublish

Résumé

To investigate the molecular cause(s) underlying a severe form of infantile-onset parkinsonism and characterize functionally the identified variants. A trio-based whole exome sequencing (WES) approach was used to identify the candidate variants underlying the disorder. In silico modeling, and in vitro and in vivo studies were performed to explore the impact of these variants on protein function and relevant cellular processes. WES analysis identified biallelic variants in WARS2, encoding the mitochondrial tryptophanyl tRNA synthetase (mtTrpRS), a gene whose mutations have recently been associated with multiple neurological phenotypes, including childhood-onset, levodopa-responsive or unresponsive parkinsonism in a few patients. A substantial reduction of mtTrpRS levels in mitochondria and reduced OXPHOS function was demonstrated, supporting their pathogenicity. Based on the infantile-onset and severity of the phenotype, additional variants were considered as possible genetic modifiers. Functional assessment of a selected panel of candidates pointed to a de novo missense mutation in CHRNA6, encoding the α6 subunit of neuronal nicotinic receptors, which are involved in the cholinergic modulation of dopamine release in the striatum, as a second event likely contributing to the phenotype. In silico, in vitro (Xenopus oocytes and GH4C1 cells) and in vivo (C. elegans) analyses demonstrated the disruptive effects of the mutation on acetylcholine receptor structure and function. Our findings consolidate the association between biallelic WARS2 mutations and movement disorders, and suggest CHRNA6 as a genetic modifier of the phenotype.

Identifiants

pubmed: 32120303
pii: S1353-8020(20)30032-8
doi: 10.1016/j.parkreldis.2020.02.003
pii:
doi:

Substances chimiques

CHRNA6 protein, human 0
Receptors, Nicotinic 0
Tryptophan-tRNA Ligase EC 6.1.1.2

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-79

Subventions

Organisme : Medical Research Council
ID : MR/K02342X/1
Pays : United Kingdom
Organisme : Department of Health
ID : RP-2016-07-019
Pays : United Kingdom
Organisme : NIH HHS
ID : P40 OD010440
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of competing interest The authors report no conflicts of interest relevant to the manuscript.

Auteurs

Simone Martinelli (S)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Viviana Cordeddu (V)

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.

Serena Galosi (S)

Department of Neuroscience, Sapienza University of Rome, Rome, Italy.

Ambra Lanzo (A)

Institute of Bioscience and BioResources, National Research Council, Naples, Italy.

Eleonora Palma (E)

Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; IRCCS San Raffaele Pisana, Rome, Italy.

Luca Pannone (L)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy; Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

Andrea Ciolfi (A)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

Michela Di Nottia (M)

Muscular and Neurodegenerative Disorders Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

Teresa Rizza (T)

Muscular and Neurodegenerative Disorders Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

Gianfranco Bocchinfuso (G)

Department of Chemical Science and Technologies, Tor Vergata University of Rome, Rome, Italy.

Alice Traversa (A)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Viviana Caputo (V)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Andrea Farrotti (A)

Department of Chemical Science and Technologies, Tor Vergata University of Rome, Rome, Italy.

Claudia Carducci (C)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Laura Bernardini (L)

Cytogenetics Unit, IRCSS Casa Sollievo della Sofferenza Foundation, San Giovanni Rotondo, FG, Italy.

Susanna Cogo (S)

Department of Biology, University of Padua, Italy.

Maria Paglione (M)

Institute of Bioscience and BioResources, National Research Council, Naples, Italy.

Martina Venditti (M)

Department of Neuroscience, Sapienza University of Rome, Rome, Italy; Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

Annarita Bentivoglio (A)

Centro per i Disturbi del Movimento, Università Cattolica del Sacro Cuore, Rome, Italy.

Joanne Ng (J)

Molecular Neurosciences, Developmental Neurosciences, UCL Institute of Child Health, London, UK.

Manju A Kurian (MA)

Molecular Neurosciences, Developmental Neurosciences, UCL Institute of Child Health, London, UK.

Laura Civiero (L)

Department of Biology, University of Padua, Italy.

Elisa Greggio (E)

Department of Biology, University of Padua, Italy.

Lorenzo Stella (L)

Department of Chemical Science and Technologies, Tor Vergata University of Rome, Rome, Italy.

Flavia Trettel (F)

Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.

Miriam Sciaccaluga (M)

IRCCS Neuromed, Pozzilli, IS, Italy.

Cristina Roseti (C)

IRCCS San Raffaele Pisana, Rome, Italy.

Rosalba Carrozzo (R)

Muscular and Neurodegenerative Disorders Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.

Sergio Fucile (S)

Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy.

Cristina Limatola (C)

Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy.

Elia Di Schiavi (E)

Institute of Bioscience and BioResources, National Research Council, Naples, Italy.

Marco Tartaglia (M)

Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy. Electronic address: marco.tartaglia@opbg.net.

Vincenzo Leuzzi (V)

Department of Neuroscience, Sapienza University of Rome, Rome, Italy. Electronic address: vincenzo.leuzzi@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH